ACCOUNTS PAYABLE |
6 Months Ended | 12 Months Ended |
|---|---|---|
Mar. 31, 2025 |
Sep. 30, 2024 |
|
| Maius Pharmaceutical Co. Ltd [Member] | ||
| Restructuring Cost and Reserve [Line Items] | ||
| ACCOUNTS PAYABLE | (9) Accounts payable ACCOUNTS PAYABLE Accounts payable consist of R&D expenses as of March 31, 2025 (unaudited), and September 30, 2024. |
(9) Accounts payable ACCOUNTS PAYABLE Accounts payable are for R&D expenses as of September 30, 2024 and 2023. |
| X | ||||||||||
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|